Illumina plans to appeal the commission’s findings. With this transaction, Illumina would have an incentive to cut off Grail’s rivals from accessing its technology, or otherwise disadvantage them.” “Illumina is currently the only credible supplier of a technology allowing to develop and process these tests. “In a race with other companies, Grail is developing a blood-based early cancer detection test,” said Margrethe Vestager, the European Commission’s executive vice president in charge of competition policy, in a statement. On Tuesday, the European Commission prohibited the Illumina-Grail merger on the grounds that it would stifle innovation and reduce choice in the market. Illumina’s makes next-generation genomic sequencing equipment and consumables, which Grail and its rivals rely on to process these early detection, multi-cancer tests.
![grail dna sequence analysis grail dna sequence analysis](https://present5.com/presentation/7546269707d07f09812f4e18dd8b64e9/image-21.jpg)
Last year, it became the first company to launch such a test commercially on a limited basis - although several rivals are on its heels. With a single blood test, Grail’s Galleri can screen asymptomatic patients for more than 50 types of cancer, many of which have no other form of screening and are often caught too late to treat.
![grail dna sequence analysis grail dna sequence analysis](https://static.wixstatic.com/media/7a082e_55c1783f64aa482688460af5215bf7a9~mv2.png)
This latest twist in Illumina’s high-stakes bid to reunite with Grail highlights the ongoing battles over how antitrust laws should apply to acquisitions of technologies that aren’t big yet but could be someday. administrative law judge found that the blockbuster $7.1 billion merger should be allowed to stand. European regulators move to block Illumina's $7.1 billion acquisition of GrailĮurope’s antitrust regulator on Tuesday moved to block San Diego’s Illumina from acquiring Grail - one week after a U.S.